Aberdeen Group
VIR icon

Aberdeen Group’s Vir Biotechnology VIR Stock Holding History

Aberdeen Group’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,390,577
Closed -$8.39M – 971
2025
Q4 		$8.39M Sell
1,390,577
-135,688
-9% -$808K 0.01% 637
2025
Q3 		$8.71M Buy
1,526,265
+519,374
+52% +$2.66M 0.01% 628
2025
Q2 		$5.07M Buy
1,006,891
+313,699
+45% +$1.68M 0.01% 702
2025
Q1 		$4.49M Buy
693,192
+330,031
+91% +$2.93M 0.01% 691
2024
Q4 		$2.67M Buy
+363,161
New +$2.86M 0.01% 730

Other funds holding VIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
GP
GSK plc London $599M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Aberdeen Group's VIR Position: Q1 2026 in Review

Aberdeen Group sold out of Vir Biotechnology (VIR) in Q1 2026, closing a stake of 1,390,577 shares — an estimated $8.39M sold.

Aberdeen Group first reported a position in VIR in Q4 2024 and held it in 5 quarters. The position peaked at $8.71M in Q3 2025. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

  • Aberdeen Group reported no remaining Vir Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Aberdeen Group sold 1,390,577 Vir Biotechnology shares in Q1 2026, an estimated $8.39M.
  • Aberdeen Group first reported a position in Vir Biotechnology in Q4 2024 and held it in 5 quarters.
  • Aberdeen Group's Vir Biotechnology position peaked at $8.71M in Q3 2025.
  • 251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.